Genitourinary Cancer News

CHICAGO — Patients with bone metastases due to urothelial carcinoma had worse outcomes than those without bone metastasis, regardless of treatment or PD-L1 expression, according to a poster presentation at ASCO Annual Meeting.

CHICAGO — Centralized treatment and adherence to modern guidelines may account for “relatively low” rates of late relapse and improved long-term outcomes after treatment for testicular cancer, according to a speaker at ASCO.

Use of robot-assisted vs. open radical cystectomy led to a significantly increased number of days alive and out of the hospital among patients with nonmetastatic bladder cancer.

Fox Chase Cancer Center and Temple Health announced several faculty appointments.

Part A of a phase 3 trial assessing adjuvant nivolumab and ipilimumab for certain patients with renal cell carcinoma failed to meet the primary endpoint of DFS, according to topline data released by the agents’ manufacturer.

CHICAGO — Savolitinib, alone or in combination with durvalumab, did not demonstrate significant efficacy in patients with advanced clear cell renal cancer, according to a presentation at ASCO Annual Meeting.

CHICAGO — In rare hereditary cancers such as paraganglioma/pheochromocytoma, where patients travel for their care, COVID caused a disruption in their screening and treatments, according to a poster presented during ASCO Annual Meeting.

Donna Hansel, MD, PhD, has been named division head of pathology and laboratory medicine at The University of Texas MD Anderson Cancer Center.

CHICAGO —Cabozantinib did not significantly extend progression-free survival in patients with metastatic urothelial carcinoma who had undergone platinum-based chemotherapy, according to data presented at ASCO Annual Meeting.

Oncology clinical trials appeared to recover from declines in enrollment and activation during the early phase of the COVID-19 pandemic, according to a study of data from two large academic centers published in Annals of Oncology.